Systemic Juvenile Idiopathic Arthritis Clinical Trials 2023

What are the top hospitals conducting SJIA research?

In the realm of clinical trials for systemic juvenile idiopathic arthritis (SJIA), several leading hospitals are making remarkable strides. One such institution is Cincinnati Children's Hospital Medical Center, situated in Cincinnati. With four active SJIA trials and a total of ten completed trials to their name, this hospital has been actively involved in researching this rare form of arthritis since recording its first trial back in 1994. Meanwhile, on the West Coast, Childrens Hospital Los Angeles is also making noteworthy contributions. Although relatively new to SJIA research with only two ongoing trials and two completed studies recorded since 2022, their dedication to advancing knowledge about this condition holds great promise.

Heading eastward to Chicago, the Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital stands out as another significant player in the field. Currently conducting one active SJIA trial and having just initiated their first recorded trial also in 2022 signifies a burgeoning interest within their team towards understanding this complex disease further. Further expanding our scope brings us to Michigan Dermatology Institute located in Waterford - even though only hosting single active investigation related to SJIA currently they managed initiation back-to-back with aforementioned hospitals starting from2022 demonstrating growing concern across multiple regions for better management against it.

Rounding off our list is the Medical University of South Carolinac arthritis (SJIA), several leading hospitals are making remarkable strides. One such institution is Cincinnati Children's Hospital Medical Center, situated in Cincinnati. With four active SJIA trials and a total of ten completed trials to their name, this hospital has been actively involved in researching this rare form of arthritis since recording its first trial back in 1994. Meanwhile, on the West Coast, Childrens Hospital Los Angeles is also making noteworthy contributions. Although relatively new to SJIA research with only two ongoing trials and two completed studies recorded since 2022, their dedication to advancing knowledge about this condition holds great promise.

Heading eastward to Chicago, the Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital stands out as another significant player in the field. Currently conducting one active SJIA trial and having just initiated their first recorded trial also in 2022 signifies a burgeoning interest within their team towards understanding this complex disease further. Further expanding our scope brings us to Michigan Dermatology Institute located in Waterford - even though only hosting single active investigation related to SJIA currently they managed initiation back-to-back with aforementioned hospitals starting from2022 demonstrating growing concern across multiple regions for better management against it.

Rounding off our list is the Medical University of South Carolina based in Charleston where researchers continue battling against SJIA through one ongoing clinical trial alongside prior involvement consistingoftwo conducted experiments dating back primarilyto2009.Such diversity among these institutions showcases not only regional commitment but nationwide collaboration aimed at improving outcomes for individuals grappling with an often devastating autoimmune disorder like systemic juvenile idiopathic arthritis.

While there may be much work ahead when it comes to understanding and treating SJIA adequately,hospitals like these serve as beacons of hope by spearheading innovative research initiatives that could potentially revolutionize patient careand bring reliefto those affected bythis debilitating condition

Which are the best cities for SJIA clinical trials?

When it comes to SJIA clinical trials, several cities emerge as frontrunners in research and advancement. Cincinnati, Ohio leads the pack with 6 active trials exploring treatments such as Ustekinumab, tofacitinib, and Emapalumab. Following closely behind are Chicago, Illinois and San Diego, California, Illinois and San Diego, California with 4 ongoing studies focused on interventions like tofacitinib, Ustekinumab, and Golimumab. Additionally, Los Angeles in California and Austin in Texas each have 3 active trials investigating treatments including Ustekinumab and Golimumab. These cities provide individuals suffering from SJIA with access to cutting-edge clinical trials that hold promise for improved care outcomes.

Which are the top treatments for SJIA being explored in clinical trials?

Clinical trials are paving the way for advancements in the treatment of systemic juvenile idiopathic arthritis (SJIA). Leading the pack is ustekinumab, currently being explored in two active SJIA trials since its listing in 2022. Another hopeful contender is emapalumab, with one ongoing trial dedicated to investigating its potential benefits for SJIA patients since 2018. Golimumab also shows promise, participating in one active trial and having been listed as a treatment option for SJIA since 2010. These innovative treatments offer new possibilities for managing this complex autoimmune condition and improving the lives of those affected by it.

What are the most recent clinical trials for SJIA?

Exciting advancements are being made in the field of systemic juvenile idiopathic arthritis (SJIA) with recent clinical trials offering hope and potential treatment options. One such trial is investigating the efficacy of ustekinumab, a medication currently undergoing Phase 3 testing. Another study focuses on emapalumab, which has also entered Phase 3 trials for SJIA patients. Additionally, tofacitinib is showing promise in an open-label phase trial as a potential treatment option for SJIA. These ongoing trials showcase the dedication and commitment of researchers to improve the lives of those affected by this challenging condition.

What SJIA clinical trials were recently completed?

The most recently completed clinical trial for Systemic Juvenile Idiopathic Arthritis (SJIA) focused on the efficacy of Abatacept. Sponsored by Bristol-Myers Squibb, this trial concluded in August 2013. Although this study provides valuable insights into the potential benefits of Abatacept as a treatment option for SJIA, further research is needed to explore more recent advancements and developments in the field.